Accepted
at 8:37 p.m. Oct, 23, 2023
by
Ahmed7
Bulk Suggestion
Bulk ID:
zarathustra/10.21.23-07:06PM
Author:
zarathustra
Co-authors:
Cameron
Type of change:
Updated content
Rationale for change
per AMBOSS, Nirsevimab is now preferred over Palivizumab (approved by FDA, July 2023)
Source: AMBOSS - https://www.amboss.com/us/knowledge/bronchiolitis/
Before
After
Extra
Extra
Extra
Extra
Text
What is used for prevention of respiratory syncytial virus (RSV) in premature infants?
{{c1::Palivizumab}}
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid









Sketchy
Ghost "pals visiting"





Sketchy 2



Picmonic
Empty field
Pixorize



Physeo
.jpg)
.jpg)

OME
Additional Resources
Empty field
One by one
Empty field